Sehydrin

Sehydrin is a drug used to treat malignant neoplasms. Let's look at the main properties of the drug, its dosage and therapeutic effect.

The antitumor agent can be used only under the supervision of a physician who has experience in using such drugs. With special caution, the drug is prescribed to patients with severe liver and kidney dysfunction. At the same time, Sehydrin is allowed for patients with jaundice with metastases in the marking.

During therapy, it is necessary to exclude the use of drugs and drinks that contain ethanol. Products with tyramine are prohibited. Since the drug is low-toxic, it can be used for patients with cytopenia that occurred during chemotherapy or radiation therapy.

[ 1 ], [ 2 ]

Indications Seguidrine

Sehydrin has an antitumor therapeutic effect. The main indications for its use are:

• Progressive inoperable forms of malignant neoplasms.
• Relapses and metastasis of malignant tumors.
• Lung cancer.
• Neuroblastoma.
• Cancer of the stomach, pancreas and other organs of the digestive system.
• Breast oncology.
• Astrocytoma, glioblastoma and other primary brain tumors.
• Fibrosarcoma and soft tissue sarcoma.
• Lymphosarcoma.
• Laryngeal cancer.
• Lymphogranulomatosis.
• Endometrial and cervical cancer.
• Desmoid carcinoma.

The drug can be used for symptomatic treatment of disseminated and locally advanced forms of malignant tumors. Sehydrin reduces the severity of pain syndrome, eliminates respiratory failure, increased weakness, fever. Improves appetite and promotes increased motor activity.

Release form

Sehydrin is available in tablet form. The tablets are coated with an enteric coating, red-brown in color. One capsule contains the active ingredient - hydrazine sulfate 60 mg. Excipients are: polymethacrylate, magnesium stearate, titanium dioxide, dimethicone and polyethyleneglycol, dibasic calcium phosphate and others. Available in blisters of 10 pieces and 50 pieces in polymer jars.

Pharmacodynamics

The active substance of the drug suppresses tumor growth. Pharmacodynamics indicates the effect of hydrazine sulfate on certain biochemical parameters. The drug reduces the permeability of cell membranes and biomembranes of subcellular structures, inhibits monoamine oxidase activity and acts as an inhibitor of xenobiotic metabolism. The antitumor effect is especially active in severe stages of cancer. The drug does not have myelosuppressive or other side effects.

Pharmacokinetics

After oral administration, the maximum concentration of the drug in the blood plasma occurs after 2 hours. Pharmacokinetics indicates accumulation and increase of the active substance in the liver, kidneys and lungs by 3-5 times. This occurs when using tablets for a long period of time.

The drug components are eliminated from intact organs affected by the tumor process and healthy ones on the 4th day of treatment. Excretion occurs with urine and is about 50% of the dose taken, partly in acetylated form. The drug is not oxidized in the body.

Dosing and administration

The method of administration and dosage of Sehydrin depend on the stage and severity of the malignant disease. The medicine is prescribed orally 1-2 hours before or 1-2 hours after meals or other medications. The recommended dosage is 1 tablet 3 times a day. The course dose is 100 tablets. If necessary, the dosage can be increased to 2 tablets per day. A repeated course of therapy can be carried out after 14 days. The number of courses is not limited, provided that the time interval is 1-3 weeks.

[ 3 ]

Use Seguidrine during pregnancy

Sehydrin is contraindicated during pregnancy and lactation. This is due to the high risk of developing pathologies in the fetus and disruption of the course of gestation. The drug is not prescribed for the treatment of children. It is used with special caution for patients with severe renal and hepatic dysfunction.

Contraindications

Sehydrin has the following contraindications for use:

• Individual intolerance to the active component and other components of the drug.
• Pregnancy and breastfeeding.
• Childhood age of patients.

The tablets are prohibited to be taken simultaneously with barbiturates and all types of alcohol.

Side effects Seguidrine

During treatment with Sehydrin, adverse reactions may develop. Side effects most often manifest as dyspeptic symptoms (nausea, vomiting, heartburn, belching), which disappear on their own after reducing the dosage. General agitation and various sleep disorders are also possible.

To eliminate pronounced dyspeptic symptoms, the use of anti-inflammatory drugs, antiemetics and antispasmodics is indicated. In case of neurotoxic effects, it is necessary to take pyridoxine hydrochloride, thiamine chloride or multivitamin preparations intravenously/orally.

Overdose

If the dose prescribed by the doctor is not followed, various pathological symptoms may appear. Overdose is manifested by dyspeptic disorders (nausea, vomiting, stool disorders), which disappear on their own after reducing the dosage or temporarily stopping treatment for 2-3 days.

Interactions with other drugs

Since Sehydrin is an antitumor agent, all its interactions with other drugs should be monitored by the attending physician. The drug is contraindicated to be taken simultaneously with tranquilizers, barbiturates, ethanol or antipsychotic drugs, as this leads to a sharp increase in the toxicity of Sehydrin. The use of the drug before other antitumor agents significantly increases their effectiveness, with the exception of Cyclophosphamide.

[ 4 ], [ 5 ]

Storage conditions

The tablets must be stored in the original packaging, protected from sunlight, moisture and out of reach of children. According to storage conditions, the temperature should be within 15-25°C. Failure to comply with these recommendations leads to premature loss of the medicinal properties of the medicine.

[ 6 ]

Shelf life

Sehydrin is approved for use for 36 months from the date of manufacture. The expiration date of this antitumor drug is indicated on the packaging. After its expiration, the drug must be disposed of.